Navigation Links
Sunshine Heart Provides C-Pulse U.S. Clinical Update
Date:7/28/2009

SYDNEY, July 28 /PRNewswire/ -- Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today that the first two patients implanted with the C-Pulse device in April 2009 at The Ohio State University Medical Center in Columbus, Ohio have successfully completed their 3 month follow-up evaluation.

Sunshine Heart's Medical Director, William Peters MD reported, "Both patients were reviewed in the outpatient clinic by hospital staff and all tests scheduled at three months were completed. Both patients appeared to have shown improvement and were able to disconnect from the device, as intended, for short periods of time. The next milestone for these patients will be evaluation at the 6 month time frame."

Don Rohrbaugh, CEO of Sunshine Heart, commented, "We are very encouraged by these patients' response with the C-Pulse device. We look forward to generating additional data from this study to support our global regulatory strategy. We are particularly pleased to report the Company received reimbursement of $108,000 from The Ohio State University for these two patients; the first such revenue for Sunshine Heart."

Six university hospitals are involved in the study, including Northwestern University, Pennsylvania State University, University of Louisville, University of Florida and University of Alabama/Birmingham as well as Ohio State University. Enrollment is expected to be completed during the first quarter of 2010. Cumulative end-point data will be released following review by the DSMB at the completion of the study.

Following the trial's successful completion, the Company will request CE Mark approval to market C-Pulse in the E.U. and other international countries that honor CE Mark label claims for device safety. In addition, the Company will seek FDA approval for a larger randomized U.S. pivotal study to support the submission of a marketing application for C-Pulse in the U.S. during the second half of 2010.

"We continue to be excited with the prospects of the C-Pulse clinical trial in the U.S." said Dr. Peters, co-founder of Sunshine Heart and inventor of C-Pulse. "As demonstrated in prior clinical studies, the C-Pulse system increases blood flow to the body and to the heart muscle itself without coming into direct contact with the blood. Importantly, the non-blood contacting feature of the device allows patients to intermittently disconnect from C-Pulse for convenience. It is anticipated that C-Pulse will offer patients a significant improvement in quality of life and with an acceptable risk profile."

For more information and a video update on C-Pulse clinical trial patients please visit the Company's website at http://www.sunshineheart.com/cpulse-first-us-patient.html.

About Advanced Heart Failure

Heart failure is a common condition in which the heart becomes unable to pump sufficient blood to meet the body's needs. Over five million people in the United States have heart failure and it results in over 300,000 deaths each year. Heart failure is a progressive condition and typically results from damage to the heart muscle arising from a heart attack or virus.

Cardiologists use a classification system to define the four classes of heart failure; each class is determined by rating a patient's symptoms to everyday activities and quality of life. Over 1.4 million US heart failure patients are in the Class III, an advanced heart failure category, which is defined by the limitation of physical activity. These patients are comfortable at rest, but levels of activity regarded as less than ordinary cause fatigue, palpitation, and/or shortness of breath. The most common treatments for Class III heart failure are drugs, lifestyle adjustments, family education, device therapy (i.e. heart failure pacemaker with or without a defibrillator), or surgery. A major medical treatment challenge is that the drug therapy and CRT options often stop alleviating symptoms over time, hence the need for C-Pulse heart assist.

About Sunshine Heart

Sunshine Heart (ASX: SHC) (www.sunshineheart.com) is a global medical device company, committed to the commercialization of C-Pulse(TM) an implantable, non-blood contacting, heart assist therapy for the treatment of people with advanced heart failure. C-Pulse reduces the symptoms of heart failure through the use of counterpulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and reduction in the heart's pumping load. The Company has received approval from the US Food and Drug Administration (FDA) to conduct a 20 person U.S. clinical trial with C-Pulse and patient enrollment has commenced. Sunshine Heart listed on the ASX in September 2004 has a presence in Australia, New Zealand and the United States of America.

For further information, please visit www.sunshineheart.com or contact:

    Contact:                             Investors/Media:
    Don Rohrbaugh                        The Ruth Group
    Chief Executive Officer              R.J. Pellegrino/Scott Lerman
    +1 714 259 0732                      646-536-7009/7013
    don.rohrbaugh@sunshineheart.com      rpellegrino@theruthgroup.com
                                         slerman@theruthgroup.com

This press release may contain forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties from time to time in the Company's filings with the Australian Securities Exchange.


'/>"/>
SOURCE Sunshine Heart
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Escape the Cold and Flu Season With a Free Vacation to the Sunshine State
2. Join the Vitamin D Revolution: How to Get 30 Minutes of Daily Sunshine for Optimal Health
3. Florida Orange Juice Adds a Healthy Splash of Flavor and Sunshine to Recipes
4. Run Your Buns off in the 26th Annual Schlotzskys(R) Bun Run(R) Benefitting Austin Sunshine Camps
5. Flower power may bring ray of sunshine to cancer sufferers
6. Let the sunshine in to protect your heart this winter
7. Sunshine vitamin link to cognitive problems in older people
8. Test Your Vitamin D Knowledge: Wellesse Liquid Sunshine Instant Win and Sweepstakes
9. Time for Change - Sunshine and Exercise Part of Holistic Treatment for Osteoporosis
10. Prescribing sunshine for multiple sclerosis?
11. Camp Sunshine Celebrates 25th Anniversary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... City, FL (PRWEB) , ... February 11, 2016 ... ... announced the commencement of a master charity program created to assist the people ... 60 days, working closely with nonprofit organizations and community leaders. Their hope is ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance Group, serving ... introduces a new charity campaign to raise funds for Ronald McDonald House Charities. ... https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally renowned nonprofit ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce ... South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge ... of their homes, offices or at the practices’ local office. It is also one ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling for American ... and wellness best practices in the past couple of decades, and food manufacturers ... Heart Month, which acts as an exceptional opportunity to revise food labels and ...
(Date:2/10/2016)... ... 10, 2016 , ... President Obama’s budget proposal yesterday enables ... medical services via telehealth, estimated to generate more than $160 million in savings ... many years. Although there is more to be done, this represents an ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... PLAD, Inc. (OTC Pink: PLAD) is pleased to announce ... company targets, are adding key personnel to their national ... United States Patent and Trademark Office for the characters ... of PLAD, Inc.  In January, PLAD established their presence ... with two new customers, Cumberland Goodwill EMS and Meadville ...
(Date:2/11/2016)... 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery , ... an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said the ...
Breaking Medicine Technology: